Core Viewpoint - The breakthrough in gene therapy and the improvement of early screening and prevention systems are providing hope for families affected by rare diseases, which impact a significant global population despite their low individual incidence [1][2]. Group 1: Rare Disease Overview - There are over 10,000 identified rare diseases globally, with approximately 80% being genetically related, affecting around 250 to 300 million people worldwide [2][3]. - Rare diseases can affect any organ or system in the body, with high mortality and disability rates, particularly in children, where over 50% of cases manifest during childhood [2][3]. - Diagnosis of rare diseases is challenging, with many conditions only identifiable through symptom-based diagnosis, leading to a "diagnostic dilemma" for patients [2]. Group 2: Genetic Basis and Inheritance - Rare diseases are primarily caused by genetic mutations, which can be inherited from parents or arise as new mutations during an individual's life [6][9]. - The inheritance patterns include recessive inheritance, X-linked inheritance, and de novo mutations, with specific implications for the likelihood of disease manifestation in offspring [6][9]. Group 3: Screening and Prevention - Early screening is crucial for preventing genetic rare diseases, focusing on three key stages: preconception, prenatal, and neonatal [9][10]. - Preconception screening can identify carrier status for genetic mutations, while prenatal diagnostics can detect inherited conditions early in pregnancy [9][10]. - Neonatal screening is essential for early intervention, with advancements in genetic testing technologies allowing for rapid diagnosis [10]. Group 4: Gene Therapy Developments - Gene therapy offers treatment options for rare diseases, primarily through gene replacement, gene editing, and RNA modification techniques [12][13]. - AAV vector technology has shown significant progress in clinical applications, particularly for spinal muscular atrophy (SMA), where treatment can lead to substantial developmental improvements [12]. - Despite advancements, gene therapy currently addresses less than 10% of rare diseases, with challenges such as delivery mechanisms and the need for early intervention remaining critical [12][13]. Group 5: Policy and Support - The Chinese government is enhancing support for rare disease research and treatment through policy initiatives, improved diagnostic technologies, and healthcare networks [3][13]. - Clinical trial information and funding opportunities for rare disease treatments are becoming more accessible, helping to alleviate the financial burden on affected families [13].

Core Insights - The conference aims to accelerate the transformation of medical research findings into practical treatments for patients, benefiting the general public [1][5] - The Guangdong-Hong Kong-Macao Greater Bay Area is highlighted for its unique advantages in enhancing collaboration and optimizing processes in clinical trials [2][3] Group 1: Conference Objectives and Structure - The conference, titled "International Clinical Trials Conference of the Guangdong-Hong Kong-Macao Greater Bay Area," focuses on improving the efficiency of clinical trials and the application of new therapies [1][3] - It emphasizes the importance of collaboration among regional medical resources to create a comprehensive innovation loop from basic research to technology breakthroughs and results transformation [3][4] Group 2: Expert Contributions and Discussions - Renowned experts, including editors from top medical journals and academicians, shared insights on clinical trial design and breakthroughs in gene therapy for rare diseases [2][4] - The conference featured discussions on optimizing treatment processes for critical conditions like cancer and cardiovascular emergencies, aiming to enhance patient outcomes [4][5] Group 3: Research and Development Focus - The conference underscored the need for research to be driven by clinical challenges, with a commitment to translating laboratory discoveries into effective clinical applications [4][5] - The Zhongshan Hospital, a key organizer, is recognized for its robust research capabilities and commitment to addressing major health issues through innovative solutions [5]